期刊
DIABETES & METABOLISM
卷 43, 期 -, 页码 2S28-2S33出版社
MASSON EDITEUR
DOI: 10.1016/S1262-3636(17)30070-8
关键词
Steatosis; GLP-1 receptor agonists; type 2 diabetes; Non-alcoholic fatty liver disease; Fibrosis
资金
- AstraZeneca/Bristol-Myers Squibb
- Bayer Pharma
- Kowa
- Lilly
- Merck Sharp Dohme
- Novartis
- Novo Nordisk
- Sanofi
- Servier
- Takeda
Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed. (C) 2017 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据